Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
Prodrugs01:30

Prodrugs

3.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

470
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
470
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.4K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.3K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining β<sub>2</sub>-AR agonism with butyrylcholinesterase inhibition, a synergistic neuroprotective action against Alzheimer's disease.

RSC medicinal chemistry·2026
Same author

Structure-Guided Discovery of a Nonpeptidic MT5-MMP Inhibitor.

ACS medicinal chemistry letters·2026
Same author

Polyfunctionalized <i>N</i>-Arylsulfonyl Indoles: Identification of (<i>E</i>)-<i>N</i>-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1<i>H</i>-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.

International journal of molecular sciences·2026
Same author

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

ACS chemical neuroscience·2026
Same author

An efficient step-by-step approach to select pleiotropic drug candidates against Alzheimer's disease: The discovery of neocopride.

Journal of Alzheimer's disease : JAD·2026
Same author

Pharmacophore-driven kinase profiling applied to the PKIS2 chemogenomic dataset.

Scientific reports·2026

Related Experiment Video

Updated: Dec 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug repositioning: a brief overview.

Jean-Pierre Jourdan1,2, Ronan Bureau1, Christophe Rochais1

  • 1UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ., Caen, France.

The Journal of Pharmacy and Pharmacology
|April 18, 2020
PubMed
Summary

Drug repositioning, using existing medications for new conditions, is a growing trend driven by new drug discovery challenges. While historically serendipitous, data mining now enables a more rational approach to identifying repositioned drugs.

Keywords:
druggenericindicationrepositioning

More Related Videos

Molecular Evolution of the Tre Recombinase
12:02

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

10.0K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Experiment Videos

Last Updated: Dec 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Molecular Evolution of the Tre Recombinase
12:02

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

10.0K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • Drug repositioning involves repurposing existing drugs for new therapeutic indications.
  • This strategy is gaining traction due to declining success rates in novel drug discovery.
  • It offers a potentially faster and more cost-effective route to new treatments.

Observation:

  • Early successes in drug repositioning, such as with acetylsalicylic acid and sildenafil, often resulted from serendipitous discoveries.
  • Despite challenges, drug repositioning demonstrates significant public health benefits and commercial value.
  • These successes highlight the untapped therapeutic potential of already-approved medications.

Findings:

  • While serendipity played a role historically, it is not a reliable method for identifying new repositioning candidates.
  • Modern approaches, particularly data mining and computational methods, allow for a more systematic and rational identification of drugs for repositioning.
  • The growing interest in drug repositioning is supported by advancements in bioinformatics and large-scale data analysis.

Implications:

  • Drug repositioning provides viable solutions for various unmet medical needs.
  • It represents a significant paradigm shift in pharmaceutical research and development.
  • Further exploration of rational drug repositioning strategies can accelerate the delivery of effective therapies to patients.